Safety and tolerability of antipsychotics: Focus on amisulpride

36Citations
Citations of this article
88Readers
Mendeley users who have this article in their library.

Abstract

The introduction of the atypical antipsychotic drugs represents an important advance in the treatment of schizophrenia, because the therapeutic efficacy, tolerability, and safety profiles of these agents seem to be superior to that of the classical neuroleptics. As would be predicted from the pharmacologic profile of a pure D2/D3 receptor blocker, amisulpride is an atypical antipsychotic agent, effective for positive and negative symptoms, which can bring about additional improvement in the social functioning and quality of life of patients with schizophrenia. Amisulpride is effective in acute schizophrenia as determined by Clinical Global Impression scores. The major concern regarding the safety of the atypical antipsychotics is related to their propensity to induce weight gain and alter glucose and lipid metabolism. Amisulpride has one of the lowest potentials for weight gain of all the antipsychotic agents, and is associated with clearly lower use of antiparkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics. Amisulpride is well tolerated with regard to anxiety and insomnia, and not notably different from placebo. Amisulpride has a pronounced prolactin-elevating effect which appears to be independent of dosage and duration of administration. Hyperprolactinemia rapidly reverses following amisulpride discontinuation. Amisulpride benefits patients with negative symptoms, and is the only antipsychotic to demonstrate efficacy in patients with predominantly negative symptoms. Amisulpride maintains its efficacy when used for medium/ long-term treatment, as demonstrated in studies of up to 12 months. In terms of relevance of the effects, superiority is observed for quality of life, social adaptation, and functioning, as measured by the Quality of Life and Functional Status Questionnaire scales. In conclusion, amisulpride is an antipsychotic agent with proven efficacy and good tolerability. Moreover, this drug can help people with schizophrenia to attain social reinsertion. © 2010 Juruena et al.

References Powered by Scopus

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

5085Citations
N/AReaders
Get full text

Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia

2196Citations
N/AReaders
Get full text

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1633Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review

297Citations
N/AReaders
Get full text

Quinoline-and isoquinoline-sulfonamide analogs of aripiprazole: Novel antipsychotic agents?

79Citations
N/AReaders
Get full text

Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics

56Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Juruena, M. F., de Sena, E. P., & de Oliveira, I. R. (2010). Safety and tolerability of antipsychotics: Focus on amisulpride. Drug, Healthcare and Patient Safety. https://doi.org/10.2147/DHPS.S6226

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 26

52%

Researcher 11

22%

Lecturer / Post doc 7

14%

Professor / Associate Prof. 6

12%

Readers' Discipline

Tooltip

Medicine and Dentistry 30

61%

Psychology 12

24%

Nursing and Health Professions 4

8%

Pharmacology, Toxicology and Pharmaceut... 3

6%

Article Metrics

Tooltip
Mentions
References: 1

Save time finding and organizing research with Mendeley

Sign up for free